This book describes a PhD research in which the
regulatory sequences of IGF2 (P3 and P4 promoters)
were used to induce killing of cancer cells in
culture or cell of mouse and rat bladder TCCs and of
rat colon metastasis to the liver.
IGF2 gene was found to be differentially
overexpressed in malignant compaired to normal
bladder tissue. Moreover, IGF2 mRNA and protein
levels were previously shown to be highly
upregulated in primary colorectal cancer and in
colon metastasis to the liver.
IGF2 plays a role in tumor development. It favors
cancer cells survival, progression and metastatic
ability of the tumor in an autocrine/paracrine
fashion. Therefore, by selective killing of cancer
cells, which overexpress IGF2, the neighboring non-
IGF2 producing tumor cells are at least partly
deprived of their IGF2 supply and thus amplifying
the therapeutic potential of IGF2 promoters driven
vectors. Such vectors were successfully shown in
this work to selectively kill malignant tissue both
in vitro and in vivo.
On the basis of the findings presented in this book,
a patient oriented approach to treat TCC and colon
metastasis in liver is proposed.
regulatory sequences of IGF2 (P3 and P4 promoters)
were used to induce killing of cancer cells in
culture or cell of mouse and rat bladder TCCs and of
rat colon metastasis to the liver.
IGF2 gene was found to be differentially
overexpressed in malignant compaired to normal
bladder tissue. Moreover, IGF2 mRNA and protein
levels were previously shown to be highly
upregulated in primary colorectal cancer and in
colon metastasis to the liver.
IGF2 plays a role in tumor development. It favors
cancer cells survival, progression and metastatic
ability of the tumor in an autocrine/paracrine
fashion. Therefore, by selective killing of cancer
cells, which overexpress IGF2, the neighboring non-
IGF2 producing tumor cells are at least partly
deprived of their IGF2 supply and thus amplifying
the therapeutic potential of IGF2 promoters driven
vectors. Such vectors were successfully shown in
this work to selectively kill malignant tissue both
in vitro and in vivo.
On the basis of the findings presented in this book,
a patient oriented approach to treat TCC and colon
metastasis in liver is proposed.